Capital Management Associates Inc Buys 15,654 Shares of Boston Scientific Corporation (NYSE:BSX)

Capital Management Associates Inc boosted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 100.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,308 shares of the medical equipment provider's stock after purchasing an additional 15,654 shares during the quarter. Boston Scientific comprises 0.7% of Capital Management Associates Inc's holdings, making the stock its 23rd biggest position. Capital Management Associates Inc's holdings in Boston Scientific were worth $3,158,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BSX. Norges Bank purchased a new position in shares of Boston Scientific in the fourth quarter worth approximately $1,762,522,000. Capital World Investors increased its position in shares of Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock worth $2,492,041,000 after acquiring an additional 6,216,199 shares in the last quarter. Wellington Management Group LLP grew its position in Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares in the last quarter. GAMMA Investing LLC grew its position in Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after purchasing an additional 2,556,078 shares in the last quarter. Finally, Axiom Investors LLC DE grew its position in Boston Scientific by 208.2% during the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock valued at $335,167,000 after purchasing an additional 2,535,007 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research analyst reports. Leerink Partners initiated coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Evercore ISI boosted their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Finally, BTIG Research reaffirmed a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.57 during trading hours on Monday, hitting $103.75. 5,892,140 shares of the company traded hands, compared to its average volume of 6,663,148. Boston Scientific Corporation has a twelve month low of $71.88 and a twelve month high of $107.53. The stock has a market capitalization of $153.49 billion, a price-to-earnings ratio of 75.73, a P/E/G ratio of 2.71 and a beta of 0.68. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average of $103.42 and a 200 day moving average of $100.22.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the prior year, the company posted $0.56 EPS. The business's revenue was up 20.9% on a year-over-year basis. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling

In other news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president owned 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,970 shares of company stock worth $47,755,193. Insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.